InsiderSignal.AI

InsiderSignal.ai

PTCT - Ptc Therapeutics, Inc.

Insider Sale by Utter Christine Marie (SVP, CHIEF ACCOUNTING OFFICER)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Utter Christine Marie, serving as SVP, CHIEF ACCOUNTING OFFICER at Ptc Therapeutics, Inc. (PTCT), sold 2,494 shares at $69.36 per share, for a total transaction value of $172,984.00. Following this transaction, Utter Christine Marie now holds 70,199 shares of PTCT.

This sale represents a 3.00% decrease in Utter Christine Marie's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, February 18, 2026 and publicly disclosed via SEC Form 4 filing on Friday, February 20, 2026, 2 days after the trade was made.

Ptc Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Utter Christine Marie

SVP, CHIEF ACCOUNTING OFFICER

Christine Marie Utter is the Senior Vice President, Chief Accounting Officer, and Head of People Services at PTC Therapeutics, Inc. (PTCT), a biopharmaceutical company focused on rare disease treatments.[[1]](https://fintool.com/app/research/companies/PTCT/people/christine-utter)[[2]](https://www.ptcbio.com/team/leadership/christine-utter/)[[5]](https://www.ptcbio.ie/about-ptc/leadership/) She joined PTC in 2010 as Assistant Controller, advanced to Senior Vice President, Finance and Principal Financial Officer from June 2017 to June 2019, and has served in her current role since June 2019, overseeing accounting operations, financial reporting, internal controls, and the company's Total Rewards global employee benefits program.[[1]](https://fintool.com/app/research/companies/PTCT/people/christine-utter)[[2]](https://www.ptcbio.com/team/leadership/christine-utter/) Utter began her career as an auditor at Arthur Andersen and Ernst & Young LLP, followed by roles as a financial analyst at Engelhard Corporation and Assistant Corporate Controller at Barrier Therapeutics from 2005 to 2009.[[1]](https://fintool.com/app/research/companies/PTCT/people/christine-utter)[[2]](https://www.ptcbio.com/team/leadership/christine-utter/) She holds a B.S. in accounting from The College of New Jersey and is a certified public accountant (CPA).[[1]](https://fintool.com/app/research/companies/PTCT/people/christine-utter)[[2]](https://www.ptcbio.com/team/leadership/christine-utter/) As of early 2025, she owns approximately 62,564 to 63,442 shares of PTCT stock, reflecting her alignment with company performance.[[3]](https://www.gurufocus.com/insider/64881/christine-marie-utter)[[4]](https://www.insidertrades.com/ptc-therapeutics-inc-stock/christine-marie-utter/)

View full insider profile →

Trade Price

$69.36

Quantity

2,494

Total Value

$172,984.00

Shares Owned

70,199

Trade Date

Wednesday, February 18, 2026

3 days ago

SEC Filing Date

Friday, February 20, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Ptc Therapeutics, Inc.

Company Overview

No company information available
View news mentioning PTCT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4154557

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime